about
Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locusThe SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARAStrategies for combining immunotherapy with radiation for anticancer therapyPredictive biomarkers in precision medicine and drug development against lung cancerBeyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesisActivation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung CancerCo-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomeThe tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignanciesAberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parametersPhase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy.Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceDynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanomaPhase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancerCharacterization of Human Cancer Cell Lines by Reverse-phase Protein ArraysAn integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.A pan-cancer proteomic perspective on The Cancer Genome Atlas.A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancerSerum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferationReciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.The BATTLE trial: personalizing therapy for lung cancer.Blasted cell line names.Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapySelective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cellsMetastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy.DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy.Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition
P50
Q21134596-4B717610-18F4-4552-B60A-74906D71C11CQ24307375-AB1EEE0B-8DC1-4013-B270-8D920863A78EQ26796675-5FEAFA6D-60F3-499E-90B9-C3F93ACA2E61Q26824536-F0869815-3C4E-485A-9C6B-2D304FD15FEFQ27026936-0506B9B8-D0FC-44D0-9204-A222E5AA940DQ27315948-D64C7F59-0B56-47DA-BB65-1782F425330AQ27345462-249C5D66-7079-47F8-AB56-16B051840D3AQ27851703-C572139A-7E07-478D-98B6-8D49B4CA10FBQ28282440-783304A4-0004-4300-A2D9-EB39DC73D8B7Q28396602-E313E01F-B3B6-417C-886B-943F72DE557AQ30424925-632DA151-242F-4018-A595-0F2363A71C42Q33211649-A77C88A2-D5D7-4570-9F5B-46A1A9989D24Q33439705-32FF29AB-2095-42A7-8906-68AFDCA7377AQ33568344-EFE9651D-913A-4209-89B7-A2D577797ED9Q33624863-A5F445EA-C607-4836-9471-DF433EA4312EQ33627739-E5CA6AF0-B09C-4CA7-A0D0-19D4000BE01EQ33709790-0A022C66-8472-4297-A9C7-91D469C7EDB1Q33759537-85EC1601-B88E-4BEC-9DA8-1541B2D9CB04Q33810763-3FF33A55-DC23-4A38-8AB9-E45889CB5D63Q33856008-AB532867-0E7C-458B-A43F-9E1CEB9D6DDAQ33882864-2EFD5DEB-B8C6-4F51-B90E-EEDA02119198Q33926952-652B1CC8-0F6D-4A3A-ABAC-64A33CA6DF7AQ33944976-40E1CC0B-50B5-44C2-BEAA-A37C29022CC2Q33946208-B07ED432-E641-4E3E-8DE1-60DB1B81851DQ34032602-CEC3EB72-F75A-4161-B813-83F2FEB676DEQ34069119-88BB3C5F-F082-4631-8AC2-6FBCD0DF9989Q34109397-E662BB05-188D-4BEF-B9CE-C9B18E120180Q34275011-E3B2125F-4A95-4F8E-AD57-00318FE0967AQ34300707-13FBD2C0-8F73-4837-B9BF-5F767B0FF3C8Q34300719-90DA20E6-C1E2-4D11-AEEB-FB5E2031FA25Q34310069-D1891268-5587-48B1-9854-5FB3EF446022Q34354339-2957BAB3-48EB-4995-B9B9-6B083A89C3A7Q34417878-95C8C289-3DEB-4F14-BA9E-692028110A19Q34458117-9F7C8B0C-434C-489D-B489-826C36F98A71Q34552576-CEFF52CD-BD27-4097-AE00-6703C01C9BB7Q34578277-E71A6731-6635-4CE2-81A9-60447CAFB187Q34781075-4922F0F2-C038-4ADF-874C-F14F38CC7AE9Q34804626-5B256900-246D-4A32-B015-2CEDD460EFAEQ34974246-755268ED-653A-436C-B587-27F5C356FDC6Q34984574-54B2C45A-D3C2-4B6D-A978-85DD19CCE9B9
P50
description
researcher
@en
wetenschapper
@nl
name
John V Heymach
@en
John V Heymach
@nl
type
label
John V Heymach
@en
John V Heymach
@nl
prefLabel
John V Heymach
@en
John V Heymach
@nl
P31
P496
0000-0001-9068-8942